Neuraminidase deficiency with beta-galactosidase deficiency

A hereditary autosomal recessive lysosomal storage disease associated with a combined deficiency of beta-galactosidase and neuraminidase, secondary to a defect in protective protein/cathepsin A (PPCA). All patients have clinical manifestations typical of a lysosomal disorder, such as coarse FACIES, cherry red spots, vertebral changes, foam cells in the bone marrow, and vacuolated LYMPHOCYTES. Three phenotypic subtypes are recognized. The early infantile form is associated with HYDROPS FETALIS; EDEMA; ASCITES, visceromegaly, skeletal dysplasia, and early death. The late infantile type is characterized by hepatosplenomegaly, growth retardation, cardiac involvement, and rare occurrence of neurologic signs. The juvenile/adult form is characterized by MYOCLONUS; ATAXIA; ANGIOKERATOMA; INTELLECTUAL DISABILITY, neurologic deterioration, absence of visceromegaly, and long survival. The majority of reported patients belong to the juvenile/adult group and are mainly of Japanese origin. Mutations in the CTSA gene have been identified. OMIM: 256540

Also Known As:

Cathepsin A Deficiency; Cathepsin A, deficiency of; Deficiency of Cathepsin A; Galactosialidosis; Goldberg syndrome; Lysosomal Protective Protein Deficiency; Lysosomal protective protein, deficiency of; Protective protein-Cathepsin A deficiency

Congenital, Hereditary, and Neonatal Diseases and Abnormalities: 933
- Inborn Genetic Diseases: 11939
  - Inborn Errors Metabolism: 1162
    - Lysosomal Storage Diseases: 2132
      - Neuraminidase deficiency with beta-galactosidase deficiency: 165
Nutritional and Metabolic Diseases: 15
- Metabolic Diseases: 10142
  - Inborn Errors Metabolism: 1162
    - Lysosomal Storage Diseases: 2132
      - Neuraminidase deficiency with beta-galactosidase deficiency: 165

P Maaswinkel-Mooy Selected Research

P Maaswinkel-Mooy Research Topics

Disease

Drug/Important Bio-Agent (IBA)